Abstract
The use of partial liquid ventilation (PLV) with perfluorocarbons in neonates, children and adults with acute lung injury/acute respiratory distress syndrome is associates with improvement in gas exchange and pulmonary function. Cardiopulmonary interaction with the long-term effects of toxicity requires further study. However, extrapolations from data obtained in animals suggests that no long-term adverse effects exist. The information available indicates that continuous monitoring is required and that ventilador should be adjusted during administration of this drug to reduce hypoxemia, hemodynamic complications and pneumothorax. Further clinical studies are required to explore the efficacy of PLV in acute lung injury/acute respiratory distress syndrome and in particular to determine the short-and long-term toxic effects. To answer these and other questions additional research is undoubtedly required.
| Original language | Spanish |
|---|---|
| Pages (from-to) | 200-207 |
| Number of pages | 8 |
| Journal | Medicina Intensiva |
| Volume | 25 |
| Issue number | 5 |
| State | Published - 2001 |
| Externally published | Yes |
Fingerprint
Keywords
- ARDS
- Liquid ventilation
- Perfluorocarbon
ASJC Scopus subject areas
- Critical Care and Intensive Care Medicine
Cite this
Ventilación líquida. / Anzueto, Antonio R; Melo, J.; Caviedes, I.
In: Medicina Intensiva, Vol. 25, No. 5, 2001, p. 200-207.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Ventilación líquida
AU - Anzueto, Antonio R
AU - Melo, J.
AU - Caviedes, I.
PY - 2001
Y1 - 2001
N2 - The use of partial liquid ventilation (PLV) with perfluorocarbons in neonates, children and adults with acute lung injury/acute respiratory distress syndrome is associates with improvement in gas exchange and pulmonary function. Cardiopulmonary interaction with the long-term effects of toxicity requires further study. However, extrapolations from data obtained in animals suggests that no long-term adverse effects exist. The information available indicates that continuous monitoring is required and that ventilador should be adjusted during administration of this drug to reduce hypoxemia, hemodynamic complications and pneumothorax. Further clinical studies are required to explore the efficacy of PLV in acute lung injury/acute respiratory distress syndrome and in particular to determine the short-and long-term toxic effects. To answer these and other questions additional research is undoubtedly required.
AB - The use of partial liquid ventilation (PLV) with perfluorocarbons in neonates, children and adults with acute lung injury/acute respiratory distress syndrome is associates with improvement in gas exchange and pulmonary function. Cardiopulmonary interaction with the long-term effects of toxicity requires further study. However, extrapolations from data obtained in animals suggests that no long-term adverse effects exist. The information available indicates that continuous monitoring is required and that ventilador should be adjusted during administration of this drug to reduce hypoxemia, hemodynamic complications and pneumothorax. Further clinical studies are required to explore the efficacy of PLV in acute lung injury/acute respiratory distress syndrome and in particular to determine the short-and long-term toxic effects. To answer these and other questions additional research is undoubtedly required.
KW - ARDS
KW - Liquid ventilation
KW - Perfluorocarbon
UR - http://www.scopus.com/inward/record.url?scp=0034920339&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0034920339&partnerID=8YFLogxK
M3 - Article
AN - SCOPUS:0034920339
VL - 25
SP - 200
EP - 207
JO - Medicina Intensiva
JF - Medicina Intensiva
SN - 0210-5691
IS - 5
ER -